FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approachLONDON and NEW YORK, Jan. 28, 2026…
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements…
BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on…
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of…
Ad hoc announcement pursuant to Art. 53 LR Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to…
Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a…
PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by…
OCALA, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the…
LONDON, UK / ACCESS Newswire / January 28, 2026 / THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE…
University of Miami Health System (UHealth) Announces a Transformational Gift from Tony and Sandra Tamer to Establish the Tamer Institute…